United States Patent 11,400,092 Landscape: Claim Scope for Thiamine Monitoring-and-Rescue in Myeloproliferative Disorders
Bottom line: U.S. Patent 11,400,092 claims a patient-treatment method that combines (1) administering “Compound I” (defined by the patent’s drug substance form, including a dihydrochloride monohydrate salt), (2) monitoring thiamine in whole blood, and (3) administering thiamine (or a thiamine equivalent) when thiamine falls below a defined reference standard (about 74 to about 222 nM/L) in patients with a myeloproliferative disorder, with dependent claim narrowing to dosing schedules, routes (IV/oral), biomarker-based measurement, specific diseases (myelofibrosis, PV, ET, AML), and optional magnesium augmentation.
What is the treatment method claimed in US 11,400,092?
Claim 1 (core): A method for treating a patient with a myeloproliferative disorder that includes three linked steps:
- Administer Compound I (or pharmaceutically acceptable salt/hydrate).
- Monitor thiamine level in the patient’s whole blood.
- Administer thiamine or a thiamine equivalent if the thiamine level is below a reference standard of about 74 to about 222 nM/L of whole blood.
Claim dependency: The patent folds in multiple layers of specificity: the disease context, how thiamine is measured, dosing magnitude (100 mg/day; 250–500 mg/day), route, scheduling, and sometimes magnesium co-management.
Scope implications of the “monitoring + threshold + rescue dosing” structure
This is not a simple thiamine supplement claim. It is a conditional regimen tied to:
- a specific biomarker threshold (74–222 nM/L whole blood),
- a specific drug-treatment context (patients receiving Compound I for a myeloproliferative disorder),
- and an action step triggered by falling below the threshold.
From an infringement perspective, the claim is easiest to satisfy when the accused regimen:
- gives Compound I to the same patient population,
- includes assaying thiamine (or thiamine deficiency biomarkers),
- and then administers thiamine only when below the threshold, or administers it as part of that conditional protocol.
What does “Compound I” cover and how does it constrain the claim?
Claim 25 states Compound I is “in the form of a dihydrochloride monohydrate salt.”
Practical constraint
Claim 1 broadly reads “Compound I or a pharmaceutically acceptable salt and/or hydrate thereof,” but the narrower dependent claim 25 anchors Compound I to a particular salt form: dihydrochloride monohydrate.
Impact on scope:
- If an accused company uses a different salt form or a different solid-state form not covered by the “Compound I” definition, claim 25 may not read.
- Claim 1 still could read if the infringer’s product qualifies as “Compound I” under the patent’s definition (which your provided text does not fully establish).
- Claim construction risk sits on whether “Compound I” is defined generically elsewhere in the specification beyond the dependent salt-form language.
What thiamine reference standard is claimed and how tight is it?
Claim 1: Reference standard is about 74 to about 222 nM/L of whole blood.
Key claim characteristics
- It is a range, not a single cutoff.
- It is tied to whole blood and to nM/L units.
- The action is triggered by being below the reference standard.
Operationally, any clinical protocol that uses a thiamine cutoff value in that range for whole blood testing and supplies thiamine (or equivalent) below cutoff is the closest conceptual match.
How is thiamine monitoring required under US 11,400,092?
Biomarker method option (Claim 2)
Claim 2: Thiamine monitoring can be done by analyzing one or more biomarkers for thiamine deficiency.
Implication: The monitoring step is not limited to direct thiamine measurement alone. It can be satisfied by an accepted biomarker strategy that correlates to thiamine deficiency.
Monitoring method breadth vs. threshold specificity
Even if biomarker-based monitoring is used, the regimen still must satisfy the below-threshold trigger (74–222 nM/L whole blood reference standard). The patent’s scope hinges on:
- whether the biomarkers are used to determine the patient is below the reference standard,
- and whether the measured/converted result corresponds to the specified whole-blood range.
What thiamine dosing amounts are claimed?
Single-day amount options (Claims 3–6)
- Claim 3: about 100 mg/day
- Claim 4: about 250 mg to about 500 mg
- Claim 5: about 250 mg
- Claim 6: about 500 mg
Whole regimen schedule (Claim 8)
Claim 8: schedule:
- ~500 mg TID for 2 or 3 days
- then 250–500 mg QD for 3–5 days
- then 100 mg QD for 90 days
“Thiamine equivalent” dosing (Claims 9, 11–14)
- Claim 9: thiamine equivalent sufficient to deliver about 100 mg/day thiamine
- Claim 11: thiamine equivalent sufficient to deliver 250–500 mg/day
- Claim 12: enough to deliver about 250 mg
- Claim 13: enough to deliver about 500 mg
- Claim 14: equivalent dosing schedule mirroring Claim 8
Route options (Claims 7, 10)
- Claim 7: thiamine administered intravenously
- Claim 10: thiamine administered orally
Infringement map: Any clinical practice that follows the conditional threshold protocol plus the claimed dosing windows and routes is directly implicated.
What disease scope is claimed for myeloproliferative disorders?
Claim 1: “myeloproliferative disorder.”
Myelofibrosis subtypes (Claims 16–21)
- Claim 16: myelofibrosis
- Claim 17: primary myelofibrosis
- Claim 18: intermediate risk or high risk primary myelofibrosis
- Claim 19: secondary myelofibrosis
- Claim 20: post essential thrombocythemia myelofibrosis
- Claim 21: post polycythemia vera myelofibrosis
Other myeloproliferative diseases (Claims 22–24)
- Claim 22: acute myeloid leukemia (AML)
- Claim 23: polycythemia vera
- Claim 24: essential thrombocythemia
Scope note: The independent claim uses broad “myeloproliferative disorder” language while dependent claims ladder down into specific hematologic conditions. That layering matters in enforcement: an accused regimen may practice the threshold thiamine rescue only in a narrower subset, allowing partial match.
What additional therapy is claimed: magnesium?
Claim 15: method further comprising increasing magnesium level.
Implication
This is a dependent claim. If an accused regimen does not manage magnesium, claim 15 would not be reached, but claim 1 and other independent branches can still be evaluated.
How broad is the claim compared with typical supplementation patents?
US 11,400,092 is structurally closer to a treatment-management patent than a pure composition patent. It claims:
- a therapeutic administration of an anti-cancer/anti-disease agent (“Compound I”),
- a monitoring protocol for thiamine status,
- and an induced corrective supplementation protocol with specified thresholds and dose ranges/schedules.
That combination creates a higher bar for infringement than a standalone thiamine formulation patent, but it can still cover real-world standard-of-care adjustments if they are implemented with the claimed threshold and timing.
What is the likely claim construction risk: “reference standard” linkage
The claims specify:
- reference standard range: 74–222 nM/L
- thiamine is monitored, and thiamine or equivalent is administered if below.
The central legal-technical linkage for scope is how the patent defines:
- what assay maps to that nM/L whole-blood standard, and
- whether biomarker-based monitoring in Claim 2 is calibrated to that same reference standard.
This can be a decisive element for both:
- validity challenges (if the science is routine and already disclosed), and
- infringement defenses (if monitoring is different and does not map to below-threshold determinations in the claimed range).
How many independent claim themes exist within the provided claim set?
From the claim text alone, there are distinct claim themes:
- Conditional thiamine monitoring + rescue threshold protocol (Claim 1).
- Biomarker-based monitoring (Claim 2).
- Dosing amount and dose range (Claims 3–6; 9; 11–13).
- Route and formulation administration (Claims 7, 10).
- Specific dosing schedule (Claims 8; 14).
- Disease subsets and risk strata (Claims 16–24).
- Magnesium co-management (Claim 15).
- Compound I salt form (Claim 25).
Each theme narrows toward a more specific practice setting, and each can be used for:
- direct infringement mapping,
- indirect infringement theories (training, instructions, protocols),
- and licensing carve-out design.
What would a competitive patent-landscape strategy look like around this claim scope?
Likely competing approaches
Companies attempting to avoid the claim may:
- use a different thiamine threshold or unit basis,
- monitor thiamine by a method that does not map to the claimed whole-blood nM/L reference range,
- provide thiamine prophylactically regardless of threshold (if prophylaxis is not “if below”),
- use thiamine amounts or schedules outside 100 mg/day and 250–500 mg/day patterns (or outside the Claim 8/14 schedule),
- avoid IV or oral dosing strategies that match the claimed route constraints (though Claims 7 and 10 are independent dependent options within the method; route avoidance would require matching strategy).
Likely enforcement target
Given the conditional nature, enforceability and licensing demand often concentrate on:
- clinical programs using Compound I in the myeloproliferative setting, where thiamine monitoring is built into study protocols and label language,
- and where actual dosing uses the claimed titration schedule.
What regulatory context matters for scope and litigation risk?
While your provided text does not include FDA labeling, the claimed regimen implies an established clinical management practice:
- measurement of thiamine levels,
- supplementation response protocols.
In the U.S., such management practices often become relevant through:
- clinical trial protocols,
- pharmacovigilance-driven recommendations,
- and label-adjacent dosing instructions.
For patent landscape purposes, programs that incorporate thiamine assays and dose-response supplementation in myeloproliferative disorders while using the patent-covered Compound I are the highest probability enforcement zones.
What is the key take-away on claim coverage breadth?
US 11,400,092 most strongly covers a specific combination:
- Compound I administration in myeloproliferative disorders,
- whole-blood thiamine measurement,
- intervention when thiamine drops below 74–222 nM/L,
- with thiamine (or equivalent) dosing in 100 mg/day or 250–500 mg/day bands and a specific multi-stage schedule,
- optionally with magnesium level increases,
- and within disease-specific subgroups including myelofibrosis (primary/secondary and post-transplant analogs), PV, ET, and AML.
Key Takeaways
- The patent is dominated by Claim 1’s conditional protocol: Compound I + whole-blood thiamine monitoring + thiamine rescue below 74–222 nM/L.
- Dependent claims narrow the regimen to biomarker monitoring, specific dosing amounts and a multi-stage schedule, oral or IV administration, and myeloproliferative disease subtypes.
- Claim 25 ties the drug identity to a dihydrochloride monohydrate salt form, strengthening linkage between “Compound I” and the claimed method.
- The monitoring threshold and schedule language create clear infringement-design “tripwires” for clinical protocols.
FAQs
- Does US 11,400,092 cover prophylactic thiamine without monitoring a 74–222 nM/L threshold?
- Can the method be infringed if thiamine monitoring is done via “thiamine deficiency biomarkers” rather than direct thiamine concentration reporting?
- How do IV versus oral thiamine routes affect infringement risk under Claims 7 and 10?
- Is the dosing schedule in Claim 8 required, or can infringement occur with any regimen using 100 mg/day or 250–500 mg/day amounts?
- Which disease subgroups in Claims 16–24 are most likely to be targeted for enforcement when Compound I is used in myeloproliferative disorders?
References
- United States Patent No. 11,400,092.
